Literature DB >> 19157997

Quantitative analysis of RU38486 (mifepristone) by HPLC triple quadrupole mass spectrometry.

Natalie Z M Homer1, Rebecca M Reynolds, Cecilia Mattsson, Matthew A Bailey, Brian R Walker, Ruth Andrew.   

Abstract

A sensitive liquid chromatography-mass spectrometric method was validated for the quantification of RU38486 (mifepristone) in human and murine plasma. The analyte and internal standard (alfaxolone) were extracted by liquid-liquid extraction with diethyl ether, resolved on a C18 column using gradient elution with methanol and ammonium acetate and detected after positive electrospray ionization (m/z 430-->372; m/z 333-->297, respectively). Quantification was linear over the range 0.5-500ng (r(2)>0.997), precise and accurate (intra-assay RSD< or =7.2%, RME< or =8.2%; inter-assay RSD< or =15.7% RME< or =10.2%). The limit of quantification (LOQ) was 50pg injected on column, permitting reproducible analysis of RU38486 in small volumes of plasma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19157997      PMCID: PMC4392796          DOI: 10.1016/j.jchromb.2008.12.051

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  13 in total

1.  Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS.

Authors:  Haijuan Dong; Fengguo Xu; Zunjian Zhang; Yuan Tian; Yun Chen
Journal:  J Mass Spectrom       Date:  2006-04       Impact factor: 1.982

2.  Automated direct assay system for RU38486, an antiprogesterone-antiglucocorticoid agent, and its metabolites using high performance liquid chromatography.

Authors:  K Nagoshi; N Hayashi; K Sekiba
Journal:  Acta Med Okayama       Date:  1991-04       Impact factor: 0.892

3.  Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.

Authors:  Peer B Jacobson; Thomas W von Geldern; Lars Ohman; Marie Osterland; Jiahong Wang; Bradley Zinker; Denise Wilcox; Phong T Nguyen; Amanda Mika; Steven Fung; Thomas Fey; Annika Goos-Nilsson; Marlena Grynfarb; Tomas Barkhem; Kennan Marsh; David W A Beno; Bach Nga-Nguyen; Philip R Kym; James T Link; Noah Tu; Dale S Edgerton; Alan Cherrington; Suad Efendic; Benjamin C Lane; Terry J Opgenorth
Journal:  J Pharmacol Exp Ther       Date:  2005-03-22       Impact factor: 4.030

Review 4.  Antiglucocorticoid drugs in the treatment of depression.

Authors:  V I Reus; O M Wolkowitz
Journal:  Expert Opin Investig Drugs       Date:  2001-10       Impact factor: 6.206

Review 5.  Clinical applications of mifepristone.

Authors:  Oi Shan Tang; Pak Chung Ho
Journal:  Gynecol Endocrinol       Date:  2006-12       Impact factor: 2.260

6.  RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day.

Authors:  R C Gaillard; A Riondel; A F Muller; W Herrmann; E E Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

7.  The new steroid analog RU 486 inhibits glucocorticoid action in man.

Authors:  X Bertagna; C Bertagna; J P Luton; J M Husson; F Girard
Journal:  J Clin Endocrinol Metab       Date:  1984-07       Impact factor: 5.958

8.  Tissue and serum levels of steroid hormones and RU 486 after administration of mifepristone.

Authors:  J D Wang; W L Shi; G Q Zhang; X M Bai
Journal:  Contraception       Date:  1994-03       Impact factor: 3.375

9.  Determination of mifepristone levels in wild canid serum using liquid chromatography.

Authors:  Charles Stith; M Delwar Hussain
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-08-25       Impact factor: 3.205

10.  Simultaneous determination of rivanol and mifepristone in human plasma by a HPLC-UV method with solid-phase extraction.

Authors:  Zhiyong Guo; Danyi Wei; Gengxin Yin; Sui Wang; Shasha Zhao; Yun Chu; Jinxia Zhai
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-06-26       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.